Cocrystal Pharma, Inc. (COCP) - 10-Q Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing broad-spectrum antiviral drug candidates for influenza, norovirus, coronavirus, and hepatitis C. This report covers the quarterly period ended June 30, 2025. The company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,055,000) | $(4,356,000) | $(9,299,000) |
| Diluted EPS | $(0.20) | $(0.43) | $(0.91) |
| Operating Expenses | $2,108,000 | $4,449,000 | $9,606,000 |
| Cash & Restricted Cash | $4,841,000 (Balance) | $4,841,000 (Balance) | $18,218,000 (Balance) |
| Operating Cash Flow | N/A | $(5,094,000) | $(8,202,000) |
| Total Assets | $8,505,000 | $8,505,000 | $13,456,000 |
| Total Liabilities | $3,172,000 | $3,172,000 | $3,933,000 |
Note: The company has no revenue and operates at a loss. Margins are not applicable.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased significantly by approximately 54% year-over-year for the six-month period (from $9.6M to $4.4M). This was driven primarily by a reduction in Research and Development (R&D) expenses, which fell from $7.3M to $2.5M.
- R&D Drivers: The decrease in R&D costs is attributed to the completion of initial heavy spending phases for the Influenza (CC-42344) and Norovirus/Coronavirus (CDI-988) clinical trials in 2024.
- Liquidity Decline: Cash and restricted cash balances dropped from $18.2M at June 30, 2024, to $4.8M at June 30, 2025, reflecting continued operating cash burn.
- Stock-Based Compensation: Stock-based compensation expense decreased from $305,000 in the first half of 2024 to $166,000 in the first half of 2025.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management explicitly states that current resources are not sufficient to fund operations beyond the next 12 months. The company has raised substantial doubt about its ability to continue as a going concern and will require additional capital to continue operations.
- Clinical Updates:
- Influenza (CC-42344): The Phase 2a human challenge study enrollment was extended due to unexpectedly low infection rates among participants. The company is discussing protocol amendments to secure sufficient data. In vitro data confirmed efficacy against the H5N1 avian flu strain.
- Norovirus/Coronavirus (CDI-988): Phase 1 results (SAD and MAD cohorts) indicated the drug was safe and well-tolerated at doses up to 1,200 mg. The company is assessing a higher dose cohort.
- Capital Strategy: The company has an At-The-Market (ATM) offering agreement but made no sales under it during the period. Future funding will likely require private or public equity offerings, which may be dilutive.
- Risks: Key risks include the inability to secure financing, delays in clinical trials, regulatory hurdles, and the potential for the company to cease operations if capital is not raised.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "less than 12 months" liquidity warning.
- Phase 2a Protocol: Confirm the status of the MHRA approval for the amended influenza study protocol to address low infection rates.
- ATM Agreement Status: Review the remaining capacity under the ATM agreement ($7.25M limit) and market conditions for potential execution.
- Related Party Leases: Note the ongoing lease commitments with a related party (Dr. Phillip Frost) for the Miami facility.
- Tax Credits: Verify the collectability of the $1.64M tax credit receivable, which is a significant portion of current assets.